Statins and statin combinations for high cholesterol
Examples
Statins
Brand Name
Generic Name
Chemical Name
Lipitor
atorvastatin
Lescol, Lescol XL
fluvastatin
Altoprev, Mevacor
lovastatin
Altocor
lovastatin, extended-release
Pravachol
pravastatin
Crestor
rosuvastatin
Zocor
simvastatin
Statin combinations
Brand Name
Generic Name
Chemical Name
Caduet
atorvastatin and amlodipine, a calcium channel blocker for high blood pressure
Advicor
lovastatin and extended-release niacin
Vytorin
simvastatin and ezetimibe, a cholesterol absorption inhibitor
How It Works
Statins block an enzyme the body needs
to produce
cholesterol. As a result,
LDL ("bad") cholesterol levels in the blood go down,
thereby lowering total blood cholesterol levels.
Statins may be
taken alone or taken with other cholesterol medicines such as fibric acid
derivatives, bile acid sequestrants, or nicotinic acid. Statins may also be
combined with other types of medicines into one drug. For example, Vytorin is a
combination medicine that lowers cholesterol in two ways: with a statin, which
blocks the production of cholesterol in the liver; and with ezetimibe, which
reduces the amount of cholesterol absorbed by the intestines.
Why It Is Used
Statins are used to lower LDL
cholesterol. Statins have been shown to lower the risk of
heart attack,
stroke, and death in people who are at high risk of a
heart attack or stroke.1
How Well It Works
Studies show that statins lower the
risk of heart attack, stroke, and death in people who have taken these
medicines to lower their cholesterol.
Studies show that intensive
cholesterol-lowering therapy decreases the progression of
coronary artery disease (CAD), compared with standard
treatment.2, 3 In the PROVE IT
study, people who recently had episodes of unstable angina or heart attacks
received higher-than-standard doses of cholesterol-lowering drugs and had fewer
subsequent heart attacks and strokes, and there were fewer deaths. This large
study suggests that intensive statin therapy could save lives. The U.S.
National Cholesterol Education Panel guidelines include more intensive
treatment with statins as an option for people who are at moderate to high risk
of heart attack.4
A review of large
clinical studies showed that statins may lower the risk of stroke in people who
are at high risk of a heart attack or stroke.1
LDL can be reduced by 18% to
55%.5 The newer, more potent statins can reduce LDL
levels even further. These statins include atorvastatin (Caduet, Lipitor) and
simvastatin (Zocor).
Triglycerides can be reduced by 7% to 30%.5 The newer, more potent statins may lower triglyceride levels
even more.
Two studies show that intensive statin treatment also
lowers levels of C-reactive protein (CRP), a biochemical marker associated with
an increased risk of CAD and heart attack. Lowering CRP along with LDL
significantly reduces heart attack and death in those who have had a previous
heart attack or unstable angina.6, 7
Side Effects
Most people do not have side effects
with statins. But possible side effects include:
Fatigue.
Upset stomach.
Gas.
Constipation.
Stomach pain or
cramps.
Minor muscle aches (not severe pain).
Severe muscle pain (not common). Severe muscle pain can be a sign
of a very serious side effect. Immediately report to your doctor any severe
muscle pain, weakness, or brown urine. Your doctor may want to do a blood test.
Muscle pain or weakness can be a sign of a severe muscle reaction (rhabdomyolysis)
and should be evaluated by your doctor.
Slight rise in liver
enzymes called transaminases. Most of the time you do not need to stop taking
the statin, unless the enzymes rise 3 or more times their normal levels.
Regular blood tests are needed to check liver function while taking
statins.
See Drug Reference for a full list of side effects. (Drug
Reference is not available in all systems.)
What To Think About
These drugs do not cause side
effects for most people who take them.
Talk to your doctor or
pharmacist about drinking grapefruit juice while you are taking a statin
medicine. Grapefruit juice can increase the level of these medicines in your
blood. Having too much medicine in your blood increases your chances of having
serious side effects.8
Studies are
focusing on combinations of statins and other medicines, such as nicotinic
acids or fibric acid derivatives. These combination medicines are useful for
lowering LDL and triglyceride levels. Statin and nicotinic acid combinations,
such as the combination drug with niacin and lovastatin (Advicor), may also
raise beneficial HDL levels in people who are at risk for CAD because of low
HDL.9, 10
Some
medicines can cause harm when taken with other medicines. People who are taking
combination statin medicines should tell their doctors if they are taking other
medicines to treat high cholesterol or triglycerides. Also, tell your doctor if
you are taking antibiotics or antifungal drugs.
The side effects
of statin medicines are more likely when higher doses are used.
Regular blood tests to check liver function are recommended, but the
frequency of testing may decrease over time. People who are taking high doses
of statins, though, should be checked more frequently. People who have liver
disease should talk to their doctors before taking these medicines.
People who are using statins should not take large amounts of niacin (a
vitamin supplement) without telling their doctors.
Women who are
pregnant or breast-feeding and anyone younger than 18 should not take
statins.
Tell your doctor about all the medicines you are taking
before using any medicine for the first time.
Gami A (2007). Secondary prevention of ischaemic
cardiac events, search date July 2004. Online version of BMJ Clinical Evidence. Also available online:
http://www.clinicalevidence.com.
Cannon CP, et al. (2004). Intensive versus moderate
lipid lowering with statins after acute coronary syndromes. New England Journal of Medicine, 350(15): 1495-1504.
Nissen SE, et al. (2004). Effect of intensive compared
with moderate lipid-lowering therapy on progression of coronary
atherosclerosis. JAMA, 291(9): 1071-1080.
Grundy SM, et al. (2004). Implications of recent
clinical trials of the National Cholesterol Education Program Adult Treatment
Panel III Guidelines. Circulation, 110(2): 227-239.
[Erratum in Circulation, 110(6): 763.]
Grundy SM, et al. (2001). Executive summary of the
third report of the National Cholesterol Education Program (NCEP) Expert Panel
on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
(Adult Treatment Panel III). JAMA, 285(19):
2486-2497.
Nissen SE, et al. (2005). Statin therapy, LDL
cholesterol, C-reactive protein, and coronary artery disease. New England Journal of Medicine, 352(1): 29-38.
Ridker PM, et al. (2005). C-reactive protein levels
and outcomes after statin therapy. New England Journal of Medicine, 352(1): 20-28.
Pasternak RC, et al. (2002). ACC/AHA/NHLBI advisory on
the use and safety of statins. Circulation, 106(8):
1024-1028.
Grundy SM (2001). United States cholesterol guidelines
2001: Expanded scope of intensive low-density lipoprotein-lowering therapy.
American Journal of Cardiology, 88(7B): 23J-27J.
Sacks FM (2001). The relative role of low-density
lipoprotein cholesterol and high-density lipoprotein cholesterol in coronary
artery disease: Evidence from large-scale statin and fibrate trials.
American Journal of Cardiology, 88(12A): 14N-18N.
This information does not replace the advice of a doctor. Healthwise disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.
Gami A (2007). Secondary prevention of ischaemic
cardiac events, search date July 2004. Online version of BMJ Clinical Evidence. Also available online:
http://www.clinicalevidence.com.
Cannon CP, et al. (2004). Intensive versus moderate
lipid lowering with statins after acute coronary syndromes. New England Journal of Medicine, 350(15): 1495-1504.
Nissen SE, et al. (2004). Effect of intensive compared
with moderate lipid-lowering therapy on progression of coronary
atherosclerosis. JAMA, 291(9): 1071-1080.
Grundy SM, et al. (2004). Implications of recent
clinical trials of the National Cholesterol Education Program Adult Treatment
Panel III Guidelines. Circulation, 110(2): 227-239.
[Erratum in Circulation, 110(6): 763.]
Grundy SM, et al. (2001). Executive summary of the
third report of the National Cholesterol Education Program (NCEP) Expert Panel
on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
(Adult Treatment Panel III). JAMA, 285(19):
2486-2497.
Nissen SE, et al. (2005). Statin therapy, LDL
cholesterol, C-reactive protein, and coronary artery disease. New England Journal of Medicine, 352(1): 29-38.
Ridker PM, et al. (2005). C-reactive protein levels
and outcomes after statin therapy. New England Journal of Medicine, 352(1): 20-28.
Pasternak RC, et al. (2002). ACC/AHA/NHLBI advisory on
the use and safety of statins. Circulation, 106(8):
1024-1028.
Grundy SM (2001). United States cholesterol guidelines
2001: Expanded scope of intensive low-density lipoprotein-lowering therapy.
American Journal of Cardiology, 88(7B): 23J-27J.
Sacks FM (2001). The relative role of low-density
lipoprotein cholesterol and high-density lipoprotein cholesterol in coronary
artery disease: Evidence from large-scale statin and fibrate trials.
American Journal of Cardiology, 88(12A): 14N-18N.